These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11990779)

  • 21. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
    Fox E; Bates SE
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.
    Kwan P; Brodie MJ
    Epilepsia; 2005 Feb; 46(2):224-35. PubMed ID: 15679503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of multidrug resistance: lessons from clinical oncology.
    Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
    Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy.
    Guns ES; Denyssevych T; Dixon R; Bally MB; Mayer L
    Eur J Drug Metab Pharmacokinet; 2002; 27(2):119-26. PubMed ID: 12064370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.
    Lum BL; Gosland MP
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):319-36. PubMed ID: 7642466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected.
    Löscher W; Luna-Tortós C; Römermann K; Fedrowitz M
    Curr Pharm Des; 2011; 17(26):2808-28. PubMed ID: 21827408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
    Padowski JM; Pollack GM
    Methods Mol Biol; 2010; 596():359-84. PubMed ID: 19949932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The transport of antiepileptic drugs by P-glycoprotein.
    Zhang C; Kwan P; Zuo Z; Baum L
    Adv Drug Deliv Rev; 2012 Jul; 64(10):930-42. PubMed ID: 22197850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.
    Bansal T; Akhtar N; Jaggi M; Khar RK; Talegaonkar S
    Drug Discov Today; 2009 Nov; 14(21-22):1067-74. PubMed ID: 19647803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy.
    Marroni M; Marchi N; Cucullo L; Abbott NJ; Signorelli K; Janigro D
    Curr Drug Targets; 2003 May; 4(4):297-304. PubMed ID: 12699350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of p38 mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats.
    Shao Y; Wang C; Hong Z; Chen Y
    J Neurochem; 2016 Mar; 136(5):1096-105. PubMed ID: 26677173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development of P glycoprotein modulators in oncology.
    Oza AM
    Novartis Found Symp; 2002; 243():103-15; discussion 115-8, 180-5. PubMed ID: 11990771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of a nitrogen atom in modulators of multidrug resistance.
    Ecker G; Huber M; Schmid D; Chiba P
    Mol Pharmacol; 1999 Oct; 56(4):791-6. PubMed ID: 10496963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2.
    Zhang C; Sarshar S; Moran EJ; Krane S; Rodarte JC; Benbatoul KD; Dixon R; Mjalli AM
    Bioorg Med Chem Lett; 2000 Dec; 10(23):2603-5. PubMed ID: 11128633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?
    Potschka H
    Epilepsia; 2010 Aug; 51(8):1333-47. PubMed ID: 20477844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in epilepsy: the role of the blood-brain barrier.
    Abbott NJ; Khan EU; Rollinson CM; Reichel A; Janigro D; Dombrowski SM; Dobbie MS; Begley DJ
    Novartis Found Symp; 2002; 243():38-47; discussion 47-53, 180-5. PubMed ID: 11990780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epilepsy and the blood-brain barrier.
    Duncan R; Todd N
    Br J Hosp Med; 1991 Jan; 45(1):32-4. PubMed ID: 2009437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy?
    Anderson GD; Shen DD
    Epilepsia; 2007 Dec; 48(12):2372-4. PubMed ID: 18088270
    [No Abstract]   [Full Text] [Related]  

  • 40. Functionalized nanocarrier combined seizure-specific vector with P-glycoprotein modulation property for antiepileptic drug delivery.
    Liu J; He Y; Zhang J; Li J; Yu X; Cao Z; Meng F; Zhao Y; Wu X; Shen T; Hong Z
    Biomaterials; 2016 Jan; 74():64-76. PubMed ID: 26447556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.